Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza: Pharmacokinetic and Pharmacodynamic Characteristics

By Widmer Nicolas  

Clinical Pharmacokinetics, Vol. 49, Iss. 11, 2010-11 ,pp. : 741-765

Adis International

Access to resources Recommend Favorite

Pathogenesis of the H5N1 avian influenza virus in humans and mammalian models

By Auewarakul Prasert  

Future Virology, Vol. 4, Iss. 2, 2009-03 ,pp. : 177-184

Future Medicine

Access to resources Recommend Favorite

The Induction of Proinflammatory Cytokines in Response to Avian Influenza H5N1 Infections and their Role in Pathogenesis and the Enhancement of Virulence

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 7, Iss. 2, 2008-01 ,pp. : 71-80

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by NanoRNA Oligonucleotides

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 7, Iss. 2, 2008-06 ,pp. : 101-105

Bentham Science Publishers

Access to resources Recommend Favorite

The World Health Organization has updated its official guidance on the clinical management of avian influenza A (H5N1) virus infection.

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 536, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite